IP Library › Granted Patent US 12,053,560
Granted Patent B2
US 12,053,560 · App. 18/502,937 · Granted Aug 6, 2024

Embolic compositions and methods

Inventors: Jeffrey Groom (Belmont, MA); Craig Wiltsey (Waltham, MA); Quynh Pham (Methuen, MA); Nikhita Mansukhani (Allston, MA); Courtney Guertin (Watertown, MA); Lee Core (Needham, MA); Upma Sharma (Somerville, MA)
Assignee: Arsenal Medical, Inc.
A61L24/06A61K47/02A61K47/34A61K49/04A61K49/0409A61L24/0021A61L24/02A61L24/043A61L24/046C08L83/04A61L2400/06A61L2430/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,053,560
App. No.
18/502,937
Granted
Aug 6, 2024
Kind
B2
Abstract

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for embolizing vasculature including the neurovasculature within a patient, among many other uses.

Claims (20)

1. A method comprising: (a) forming a crosslinkable composition for vascular embolization comprising:

(i) providing a first fluid composition comprising (A) a polysiloxane having two or more unsaturated groups and (B) a first imaging agent having an average primary particle size from 80 nm to 200 nm;

(ii) providing a second fluid composition comprising (A) a hydride material having two or more hydride groups and (B) a second imaging agent having an average primary particle size from 80 nm to 200 nm; and

(iii) mixing the first fluid composition and the second fluid composition with a dry composition, the dry composition comprising a first silica filler and, optionally, a second silica filler that is the same or different from the first silica filler;

thereby forming the crosslinkable composition, wherein the first imaging agent, the second imaging agent, the first silica filler, and the optional second silica filler are substantially evenly dispersed in the crosslinkable composition;

(b) preparing the crosslinkable composition for injection; and

(c) injecting the crosslinkable composition into an injection site within a vasculature of a patient whereupon the crosslinkable composition substantially flows into and occludes a plurality of distal vessels in the vasculature, wherein at least one distal vessel in the plurality of distal vessels has a diameter of less than 100 microns, and whereafter the crosslinkable composition substantially flows into and occludes the plurality of distal vessels in the vasculature, the crosslinkable composition crosslinks and forms into a solid.

2. The method of claim 1 , wherein the first imaging agent is bismuth trioxide.

3. The method of claim 1 , wherein the second imaging agent is bismuth trioxide.

4. The method of claim 1 , wherein the method is a method for (1) occlusion of the vasculature for treatment of tumors, (2) pre-surgical embolization of tumors, (3) treatment of chronic subdural hematoma, brain aneurysms, arteriovenous malformations, arteriovenous fistulas, gastrointestinal bleeds, bleeding due to trauma, abdominal aortic aneurysm, intracranial aneurysm, pulmonary aneurysm, or hemorrhage, (4) prostate artery embolization or uterine artery embolization, (5) treatment of visceral aneurysms, varicoceles, or varices, (6) treatment for pelvic congestion, (7) treatment of epistaxis or (8) treatment of endoleaks.

5. The method of claim 1 , wherein the crosslinkable composition is injected into the vasculature via an inflatable balloon catheter.

6. The method of claim 5 , wherein a balloon of the balloon catheter is inflated at a site proximal to the injection site and maintained in place for a period of time following injection of the crosslinkable composition.

7. The method of claim 1 , wherein the first silica filler and the second silica filler, if present, are fumed silica.

8. The method of claim 1 , wherein the first silica filler and the second silica filler, if present, are hydrophobic.

9. The method of claim 1 , wherein the second fluid composition comprises a second hydride material having two or more hydride groups.

10. The method of claim 1 , wherein the crosslinkable composition comprises a total amount of at least 10 wt % of bismuth trioxide in each of the first fluid composition and second fluid composition.

11. The method of claim 1 , wherein the ratio of the volume of the first fluid composition to the volume of the second fluid composition is in the range of from 4:1 to 1:4.

12. The method of claim 1 , wherein the polysiloxane has a weight average molecular weight ranging from 250 Da to 10,000 Da.

13. The method of claim 1 , wherein the polysiloxane has a weight average molecular weight ranging from 300 to 13,000 Da.

14. The method of claim 1 , wherein the crosslinkable composition contains a catalyst modifier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2024
From: GROOM, JEFFREY; WILTSEY, CRAIG; PHAM, QUYNH; MANSUKHANI, NIKHITA; GUERTIN, COURTNEY; CORE, LEE; SHARMA, UPMA
To: ARSENAL MEDICAL, INC.
Reel/Frame 066664/0233 →
Continuity (4)
Continuation 18322852 · May 24, 2023
Continuation 18001024
Provisional Application 63036564 · Jun 9, 2020
Related Publication 20240091401A1 · Mar 21, 2024
Cited By (9)
US 12,285,537 US 12,285,538 US 12,296,065 US 12,357,724 US 12,364,787 US 12,370,285 US 12,370,286 US 12,478,710 US 12,521,467